Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market [Yahoo! Finance]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
EXTON, PA, May 01, 2024 (GLOBE NEWSWIRE) -- In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus area for gene therapy investigation. With gene therapies representing the forefront of personalized medicine, and retinal disorders at the edge of the frontier, Spherix Global Insights conducted a study with practicing retinal specialists (n=77) to assess the current landscape and what would be required for integrating these pioneering therapies into future practice. While development potential and interest for this novel treatment approach is high for more rare inherited conditions such as retinitis pigmentosa and Stargardt's, Spherix's study zeroed in on highly prevalent degenerative disorders such as geographic atrophy (GA), age-related macular degeneration (AMD), and diabetic macular edema (DME). These conditions profoundly impact central vision later in life, thus emphasizing the critical need
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Inc. (NASDAQ: RGNX) had its price target raised by analysts at HC Wainwright from $36.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Upcoming Investor ConferencesPR Newswire
- REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
RGNX
Earnings
- 5/8/24 - Miss
RGNX
Sec Filings
- 5/14/24 - Form 144
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- RGNX's page on the SEC website